Inspection reveals QbD-minded FDA

API maker Hovione, following a successful FDA pre-approval inspection of its manufacturing plant in Macau, near Hong Kong, notes that "the FDA is looking in far greater detail to aspects like Quality by Design and supply chain management." The regulator scrutinized preventive and corrective action implementation and follow-up, as well as water systems operation, according to a Hovione announcement.

Under what the company calls the "new FDA approach," inspectors examining the softened water system looked at its design, operational and performance qualification, as well as the previous year's annual report to judge system performance. "But on top of this they expect permanent monitoring of several operational parameters of the system, municipal water quality, and performance of the municipal water system."

QbD, despite great expectations for streamlining the regulatory approval process, has proven itself not much of a headline-grabber. Its development both within the FDA via its QbD pilot and outside of the regulator's domain sometimes appears slower than that of industry standards. But then an announcement like Hovione's or, as reported earlier, a Genentech conference presentation, show that progress is being made behind the scenes.

- see the Hovione release
- here's our Genentech/FDA pilot coverage

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)